Last edition
News about "ReGenTree announces results of additional analysis"
ReGenTree LLC, a US joint venture company between GtreeBNT and RegeneRx announced results of additional analysis of the phase 3 clinical trial ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye
ReGenTree Announces Results Of Additional Analysis | 15/05/2021 | By Darshana | 477
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members